DPP4 and metabolic syndrome: Sitagliptin, one of the DPP-4 inhibitors, has been shown to decrease MetS, obesity-induced adipose tissue inflammation, and fatty liver by regulating the adenosine monophosphate-activated protein kinase and adiponectin levels in obese mice [283].